非家族性生长激素细胞腺瘤的发病机制
本文综述了非家族性生长激素细胞腺瘤的发病机制,重点阐述了GHRH-GHRHR信号通路通过cAMP驱动GH过量分泌和细胞增殖,并诱导DNA损伤和衰老表型。cAMP通路可能是此类腺瘤的核心分子驱动因素,影响其对靶向cAMP通路治疗的反应。
要点
- cAMP通路是生长激素细胞腺瘤发病的主要分子驱动因素。
- GNAS突变等异常导致持续性cAMP信号,促进GH分泌和细胞增殖。
- cAMP信号增强还诱导DNA损伤和衰老表型,与GH过度产生相关。
核心结论
- cAMP通路似乎是生长激素细胞腺瘤发病的主要分子驱动因素。
- 升高的cAMP驱动GH过度分泌和生长激素细胞增殖,并诱导DNA损伤,表现为基因组不稳定性增加和衰老特征。
研究设计与样本
- 通过PubMed检索关于肢端肥大症患者非家族性生长激素细胞腺瘤发病机制中信号通路和分子驱动因素的英文原创研究和综述。
主要发现
- 生长激素细胞表达GHRH和生长抑素的G蛋白偶联受体。
- GHRH通过其受体GHRHR信号传导,增加细胞内cAMP水平,介导GH转录和分泌以及细胞谱系发育、增殖和分化。
- GNAS点突变及其他基因组和非基因组异常导致GHRH-GHRHR信号通路持续cAMP信号,诱导GH产生和生长激素细胞增殖,可能促进散发性生长激素细胞腺瘤的发展。
- 增强的cAMP信号增加DNA损伤标志物并激活DNA损伤应答通路,导致与GH过度产生密切相关的衰老腺瘤表型。
临床怎么用
- 这些发现阐明了此类腺瘤生物学行为的分子框架及其对靶向cAMP依赖性通路治疗(包括生长抑素受体配体)的反应性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Excess growth hormone (GH) production leading to acromegaly most commonly emanates from an adenomatous pituitary somatotroph. Understanding the pathogenesis of these adenomas will elucidate how biologic behavior affects acromegaly treatment outcomes. EVIDENCE ACQUISITION: We searched PubMed for relevant English-language original research and review articles on signaling pathways and molecular drivers implicated in the pathogenesis of nonfamilial somatotroph adenomas in patients with acromegaly. EVIDENCE SYNTHESIS: Somatotroph cells express cognate G protein-coupled receptors for both hypothalamic stimulatory GH-releasing hormone (GHRH) and inhibitory somatostatin. Somatotroph GH transcription and secretion, as well as somatotroph cell lineage development, proliferation, and differentiation, are mediated by GHRH signaling through its cognate receptor (growth hormone-releasing hormone receptor [GHRHR]), driving increased intracellular cyclic adenosine monophosphate (cAMP) levels. Point mutations in GNAS and other genomic and nongenomic aberrations in the tightly regulated GHRH-GHRHR signaling pathway result in persistent cAMP signaling, inducing GH production and somatotroph proliferation, and potentially favoring the development of sporadic somatotroph adenomas. Enhanced cAMP signaling also increases DNA damage markers and activates DNA damage response pathways, leading to a senescent adenomatous phenotype tightly linked to GH overproduction. CONCLUSION: The cAMP pathway appears to be a dominant molecular driver of somatotroph adenoma pathogenesis. Elevated cAMP drives GH hypersecretion and somatotroph proliferation and also induces DNA damage, as evidenced by increased genomic instability and a senescent signature. Collectively, these findings elucidate a molecular framework for the biological behavior of these adenomas and their responsiveness to therapies targeting cAMP-dependent pathways, including somatostatin receptor ligands.
引用
- Ben-Shlomo A, Melmed S. Pathogenesis of nonfamilial somatotroph adenomas. J Clin Endocrinol Metab. 2026. PMID: 41824769. doi:10.1210/clinem/dgag116
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。